Leukemia Research
Volume 30, Issue 6 , Pages 701-705 , June 2006

Chronic myeloid leukemia after treatment of lymphoid malignancies: Response to imatinib mesylate and favorable outcomes in three patients

  • Jeyanthi Ramanarayanan

      Affiliations

    • Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
    • ,
  • Lauren M. Dunford

      Affiliations

    • Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
    • ,
  • Maria R. Baer

      Affiliations

    • Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
    • ,
  • Sheila N.J. Sait

      Affiliations

    • Clinical Cytogenetics Laboratory, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
    • ,
  • William Lawrence

      Affiliations

    • Century Medical Group, Buffalo, NY, USA
    • ,
  • Philip L. McCarthy

      Affiliations

    • Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
    • Corresponding Author InformationCorresponding author. Present address: Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. Tel.: +1 716 845 1051; fax: +1 716 845 3272.

Received 3 September 2005 ,Revised 26 October 2005 ,Accepted 29 October 2005.

References 

  1. Aguiar RC. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998;29(1–2):17–26
  2. Deininger MW, Bose S, Gora-Tybor J, et al. Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res. 1998;58(3):421–425
  3. Brill AB, Tomonaga M, Heyssel RM. Leukemia in man following exposure to ionizing radiation. A summary of the findings in Hiroshima and Nagasaki, and a comparison with other human experience. Ann Intern Med. 1962;56:590–609
  4. Corso A, Lazzarino M, Morra E, et al. Chronic myelogenous leukemia and exposure to ionizing radiation—a retrospective study of 443 patients. Ann Hematol. 1995;70(2):79–82
  5. Hsiao HH, Liu TC, Chang CS, et al. Secondary chronic myelogenous leukemia after autologous peripheral blood stem cell transplantation for lymphoma. Int J Hematol. 2001;73(1):126–128
  6. Waller CF, Fetscher S, Lange W. Secondary chronic myelogenous leukemia after chemotherapy followed by adjuvant radiotherapy for small cell lung cancer. Leuk Res. 1999;23(10):961–964
  7. Jackson GH, Latham JA, Lennard AL, et al. Rapid onset of chronic granulocytic leukaemia after treatment for Hodgkin's disease. Br J Haematol. 1994;87(1):193–195
  8. Numata A, Shimoda K, Gondo H, et al. Therapy-related chronic myelogenous leukaemia following autologous stem cell transplantation for Ewing's sarcoma. Br J Haematol. 2002;117(3):613–616
  9. Salvagno L, Soraru M, Leszl A, et al. Prolonged survival (17 years) in a patient with chronic myelogenous leukemia after therapy for Hodgkin's disease. Leuk Lymphoma. 1994;16(1–2):177–181
  10. Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol. 1986;4(6):830–837
  11. Valagussa P, Santoro A, Fossati Bellani F, et al. Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Blood. 1982;59(3):488–494
  12. Maher VE, Gill L, Townes PL, et al. Simultaneous chronic lymphocytic leukemia and chronic myelogenous leukemia. Evidence of a separate stem cell origin. Cancer. 1993;71(6):1993–1997
  13. Nanjangud GJ, Saikia TK, Chopra H, et al. Development of Ph positive chronic myeloid leukemia in a patient with chronic lymphocytic leukemia treated with total body irradiation: a rare association. Leuk Lymphoma. 1996;22(3–4):355–359
  14. Salim R, Wang L, Lin K, Clark RE. Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia. Leuk Lymphoma. 2002;43(11):2225–2227
  15. Teichmann JV, Sieber G, Ludwig WD, et al. Chronic myelocytic leukemia as a second neoplasia in the course of chronic lymphocytic leukaemia. Case report and review of the literature. Leuk Res. 1986;10(4):361–368
  16. Whang-Peng J, Young RC, Lee EC, et al. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood. 1988;71(2):403–414
  17. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol. 1998;16(2):536–544
  18. Mossafa H, Fourcade C, Pulic M, et al. Chronic lymphocytic leukemia associated with myelodysplastic syndrome and/or chronic myeloid leukemia: evidence for independent clonal chromosomal evolution. Leuk Lymphoma. 2001;41(3–4):337–341
  19. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood. 1998;91(6):1833–1844
  20. Forrest DL, Nevill TJ, Naiman SC, et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplant. 2003;32(9):915–923
  21. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12(12):2527–2534
  22. Mach-Pascual S, Legare RD, Lu D, et al. Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood. 1998;91(12):4496–4503
  23. Bauduer F, Ducout L, Dastugue N, Marolleau JP. Chronic myeloid leukemia as a secondary neoplasm after anti-cancer radiotherapy: a report of three cases and a brief review of the literature. Leuk Lymphoma. 2002;43(5):1057–1060
  24. Waller CF, Fetscher S, Lange W. Treatment-related chronic myelogenous leukemia. Ann Hematol. 1999;78(8):341–354
  25. Prebet T, Michallet AS, Charrin C, et al. Secondary Philadelphia chromosome after non-myeloablative peripheral blood stem cell transplantation for a myelodysplastic syndrome in transformation. Bone Marrow Transplant. 2004;33(2):247–249
  26. Waldman D, Weintraub M, Freeman A, et al. Favorable early response of secondary chronic myeloid leukemia to imatinib. Am J Hematol. 2004;75(4):217–219
  27. Lokeshwar N, Kumar L, Kumari M. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma. 2005;46(5):781–784
  28. Appel S, Balabanov S, Brummendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells. 2005;23(8):1082–1088
  29. Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004;18(8):1332–1339
  30. Seymour JF, Juneja SK, Campbell LJ, et al. Secondary acute myeloid leukaemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia. 1999;13(11):1735–1740
  31. Davies SV, Murray JA, Bowser-Riley SM. Secondary leukemia with a translocation (8;21)?. Cancer Genet Cytogenet. 1988;31(2):271–274
  32. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21(11):2123–2137

PII: S0145-2126(05)00414-5

doi: 10.1016/j.leukres.2005.10.015

Leukemia Research
Volume 30, Issue 6 , Pages 701-705 , June 2006

Article Tools